

Borderline peak plasma cortisol following Synacthen stimulation – single-centre analysis of three years' data

Burn S¹, Colyer S¹, Dimitri PJ¹, Wright NP¹, Krone NP^{1,2}, Elder CJ^{1,2}

¹Sheffield Children's Hospital, ²The University of Sheffield, Sheffield UK

Background

- Worldwide, the Short Synacthen Test (SST) is the most frequently performed diagnostic test for adrenal insufficiency (AI) in children.¹
- Diagnostic cut-offs for peak plasma cortisol may be difficult to determine due to:
 - Non-specific clinical features of AI.²
 - Increased sensitivity and specificity of different cortisol assays.³
 - "Borderline" results may be interpreted and managed variably by different clinicians.⁴

Aim

To examine cases with borderline peak plasma cortisol following SST to identify aetiological links and common management strategies.


Methods

- Dataset: 433 SSTs from 2014-2017
- "Borderline" cases defined as a peak cortisol following synacthen stimulation of >300 but <450 nmol/L.
- Cortisol assay: Abbott Architect chemiluminescent immunoassay (CVs <5%).
- Data extracted:
 - SST patient demographics
 - SST dose: 1 mcg low-dose (LD) or 250 mcg standard dose (SD)
 - SST indication: weaning from steroids, clinically suspected AI or pituitary dysfunction
 - SST result categorised by:
 - Pass >449 nmol/L
 - Fail <300 nmol/L
 - Borderline: 300-349, 350-399, 400-449
 - Physician management following SST result

Results

- SSTs categorised as "borderline": 74/433 (17.1%)
 - M41, F33
 - Age distribution: 0-1yr: 8%, 2-5yrs: 11%, 6-10yrs: 27%, 11-15yrs: 39%, 16+yrs: 15%
 - SD: 60.8%, LD: 31.1%, dose unknown: 8.1%
- Number of borderline results remained similar over study period despite increasing numbers of SSTs (fig 1)


Fig 1: Number and results of SSTs performed by year



There are no conflicts of interest and the authors have nothing to declare

- There was an increasing trend towards using SD over LD SST (47.4% SD 2014-15 vs 87.5% SD 2016-17)
- Following SST physician management strategies differed depending on:
 - The dose of synacthen used for the test
 - Which category of "borderline" the result fell into
 - Whether the child was already on replacement steroids
 - The index of suspicion for AI
- 23% of 'borderline' cases were managed with "sick day rule" steroid cover only (59% previously on daily oral steroid, 41% not)
- Steroid dose was more likely to be weaned after standard dose SST (33.3%) compared to low-dose SST (17.4%) (fig 2a+b)

Figure 2: Management of "borderline" cortisol results following SST



- 83% of SST performed in patients not already on daily oral steroids were done for clinical suspicion of AI. Following a 'borderline' result 29% of these were commenced on steroids (daily replacement or sick days rules only).
- Overall 6 new cases of AI were identified from 'borderline' cortisol results over 3 years (8.1% of borderline SSTs)

Discussion

- Our local practice has changed – more tests are being performed, a greater proportion use the standard dose, but the numbers of results between 300-449 nmol/L has remained static.
- There is variation in the interpretation of an SST depending on the indication of the test, dose of Synacthen used and whether the patient is already on steroids.
- Provision of 'sick day rules' for children with "borderline" results may provide a more pragmatic management approach but the efficacy & safety of this approach requires further study.

References

- Cross AS *et al.* International survey on high and low-dose synacthen test and assessment of accuracy in preparing low-dose synacthen. *Clinical Endocrinology* 2018; 88: 744-751.
- Park *et al.* The diagnosis and treatment of adrenal insufficiency during childhood and adolescence. *Archives of Disease in Childhood* 2016; 101(9): 860-865.
- Kline *et al.* Clinical implications for biochemical diagnostic thresholds of adrenal sufficiency using a highly specific cortisol immunoassay. *Clinical Biochemistry* 2017; 50(9): 475-480.
- Hawcutt DB *et al.* Adrenal responses to Low Dose SST in children with asthma. *Clinical Endocrinology* 2015; 82: 648-656.